Journal Information
Vol. 111. Issue 7.
Pages 545-560 (September 2020)
Vol. 111. Issue 7.
Pages 545-560 (September 2020)
DOI: 10.1016/j.adengl.2020.08.005
Open Access
Porokeratosis: A Review of its Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment
Poroqueratosis. Revisión de su etiopatogenia, manifestaciones clínicas, diagnóstico y tratamiento
P. Vargas-Moraa, D. Morgado-Carrascob,
Corresponding author

Corresponding author.
, X. Fustà-Novellc
a Departamento de Dermatología, Facultad de Medicina, Universidad de Chile, Santiago, Chile
b Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain
c Servicio de Dermatología, Althaia, Xarxa Assistencial Universitària de Manresa, Spain
Article information
Full Text
Download PDF
Figures (6)
Show moreShow less
Tables (4)
Table 1. Clinical and Epidemiological Characteristics of the Various Subtypes of Porokeratosis.
Table 2. Cases Described in the Literature of Eruptive Disseminated Porokeratosis Associated With Malignancy.
Table 3. Differential Diagnosis for Porokeratosis.
Table 4. Treatment of Porokeratosis and Clinical Response.
Show moreShow less

Porokeratosis comprises a group of heterogeneous and uncommon acquired or congenital skin diseases of unknown origin characterized by a keratinization disorder resulting from abnormal clonal expansion of keratinocytes. Numerous genetic mutations are thought to be involved. These conditions are characterized histologically by the presence of a cornoid lamella. Clinical manifestations are variable, with localized, disseminated, and even eruptive forms. Porokeratosis has been associated with immunosuppression, ultraviolet radiation, and systemic, infectious, and neoplastic diseases. Many authors consider it to be a premalignant condition because of the potential for malignant transformation to squamous cell or basal cell carcinoma. Therefore, long-term follow-up is a key component of treatment, which is usually complex and often unsatisfactory. We review the latest advances in our understanding of the pathogenesis, diagnosis, and treatment and propose a treatment algorithm.

Porokeratosis of Mibelli
Linear porokeratosis
Eruptive porokeratosis
Skin cancer

Las poroqueratosis son un grupo heterogéneo e infrecuente de dermatosis adquiridas o heredadas de etiología desconocida, caracterizadas por un trastorno de la queratinización secundario a una expansión clonal anormal de los queratinocitos. Se han descrito múltiples mutaciones genéticas potencialmente implicadas. Histológicamente, se caracterizan por la presencia de la lamela cornoide. Su presentación clínica es variable con formas localizadas, diseminadas e incluso eruptivas. Las poroqueratosis se han asociado con inmunosupresión, radiación ultravioleta, enfermedades sistémicas, infecciosas y neoplásicas. Muchos autores las consideran como entidades premalignas dada su potencial degeneración neoplásica a carcinoma escamoso o basocelular. Por ello, el seguimiento a largo plazo es uno de los pilares de su tratamiento, el que suele ser complejo y a menudo insatisfactorio. En la presente revisión se discuten los últimos avances en su etiopatogenia, diagnóstico y terapéutica, y se propone un algoritmo de tratamiento.

Palabras clave:
Poroqueratosis de Mibelli
Poroqueratosis lineal
Poroqueratosis eruptiva
Cáncer cutáneo
Full Text

Porokeratosis constitutes a rare group of acquired or inherited skin disorders of unknown etiology characterized by aberrant keratinization. Multiple clinical variants have been described, each with varying morphology, distribution, and clinical course. Given its potential for malignant transformation to squamous or basal cell carcinoma, many authors consider porokeratosis to be a premalignant condition.1,2 In this article, we review general aspects of porokeratosis, with a focus on disseminated superficial actinic porokeratosis (DSAP), disseminated superficial porokeratosis (DSP), porokeratosis of Mibelli (PM), linear porokeratosis (LP), eruptive disseminated porokeratosis (EDP), porokeratosis plantaris palmaris et disseminata (PPPD), punctate porokeratosis (PP), and other more recently described clinical variants. We also provide a brief overview of the evidence available on different treatment options.


Porokeratosis is a rare disorder but its exact incidence and prevalence are unknown. It generally affects adults, although certain variants such as PM and DSP can develop in childhood.1,2 No ethnic or racial differences have been described.1 Data from some series suggest that porokeratosis, in particular PM and PPPD, may be more common in men.3,4 LP and DSAP, by contrast, appear to be more common in women.1 DSAP is directly associated with UV radiation and mainly affects whites, hence its relatively high prevalence in countries such as Australia.1

Etiology and Pathogenesis

Although porokeratosis is thought to arise from an abnormal clonal proliferation of keratinocytes, its etiologic and pathogenic mechanisms are unknown.2 Parakeratosis may be due to altered maturation of keratinocytes or acceleration of epidermopoiesis. Premature apoptosis of keratinocytes underlying the cornoid lamella has been observed together with loss of the granular layer and altered loricrin and filaggrin expression.5

Multiple etiologic and pathogenic factors, described below, have been implicated.

  • a.

    Genetic Factors

A significant number of familial cases of porokeratosis, inherited as an autosomal dominant condition with variable penetrance, have been reported for PM, LP, DSAP, DSP, and PPPD.1,2 Certain sporadic cases are assumed to be due to somatic mutations. It has been postulated that the various forms of porokeratosis might be different phenotypes with a common genetic alteration.2 Multiple genetic loci have been described. The most widely studied variant is DSAP, for which 5 loci have been identified on chromosomes 1, 12, 15, 16, and 18; other loci have been found at 12q23.2–24.1, near the gene responsible for Darier disease, and at 18p11, a susceptibility locus for psoriasis.6–10 A sixth locus on chromosome 12 has also been implicated in PPPD,11but it has been suggested that these cases might actually correspond to PM.12

Genetic mutations in the mevalonate pathway have been linked to DSAP, as they have a role in keratinocyte differentiation and in protecting against UV radiation–induced apoptosis.13 Alteration of this pathway has been observed in 33% of familial cases and 16% of sporadic cases of DSAP.14 Other potentially involved genes, which have a role in epidermal differentiation, are SSH1, SART3, and SLC17A9.15 Localized forms of porokeratosis such as PM and LP may be due to mosaicism (focal loss of heterozygosity through somatic mutations). This would explain the link between localized forms and DSAP in some patients.16

  • b.

    UV Radiation

The association between UV radiation and porokeratosis is mainly based on findings from experimental and observational studies showing lesions in sun-exposed areas, worsening during summer months, a higher incidence in areas with high sun exposure, and lesions induced by phototherapy.1,17 Nonetheless, there have also been reports of improvement with phototherapy, and DSAP does not tend to affect the face.1

  • c.


Porokeratosis has also been linked to immunosuppression (particularly in relation to solid organ and bone marrow transplants),1,18 hematologic malignancies, human immunodeficiency virus infection, drugs, and inflammatory and/or autoimmune diseases. Porokeratosis has a reported incidence of 10% in kidney transplant patients, with a time from transplant to onset ranging from 4 months to 14 years (mean, 4–5 years).19 The most common variants of porokeratosis seen in immunosuppressed patients are DSAP and PM, or both simultaneously.18

The mechanism underlying the link between porokeratosis and immunosuppression is uncertain, although some studies have shown increased expression of HLA-DR antigens in epidermal Langerhans cells in porokeratosis lesions,19 possibly indicating altered immunosurveillance resulting in the clonal proliferation of abnormal keratinocytes.

  • d.

    Other Factors

There have been isolated reports of porokeratosis developing in relation to certain drugs, including suramin, hydrochlorothiazide, furosemide, hydroxyurea, gentamicin, exemestane, flucloxacillin,20,21 and biologics such as etanercept, certolizumab, and trastuzumab.21–23

Porokeratosis has been linked to infections involving human papillomavirus, herpes simplex virus, hepatitis C virus [HCV], and leishmania1,24 and to systemic diseases, such as Crohn disease, chronic liver disease, chronic kidney failure, primary cardiac amyloidosis, acute pancreatitis, Sjögren syndrome, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and, mainly in the case of DSP, diabetes mellitus.25–27 It has also been linked to certain genetic disorders, such as trisomy 16, craniosynostosis-anal anomalies-porokeratosis syndrome, Nijmegen breakage syndrome, cystic fibrosis, Werner syndrome, erythropoietic protoporphyria, Rothmund-Thomson syndrome, and Bardet-Biedl syndrome.1,28 Skin disorders associated with porokeratosis include lichen planus, psoriasis, pemphigus, hydradenitis suppurativa, alopecia areata, pyoderma gangrenosum, discoid lupus, vitiligo, and lichen sclerosus.1,29

One serious association is that between porokeratosis and hematologic malignancies or solid organ tumors. This association is particularly strong for EPD (present in up to one-third of patients) and many of the cases have criteria suggestive of a paraneoplastic manifestation.30,31 The association could be due to paraneoplastic immunosuppression or to the coexistence of viral infections such as HCV infection, which can cause mutations that disrupt the function of the tumor suppressor p53 gene.30

There have also been reports linking porokeratosis to traumatic factors, as lesions have been observed at hemodialysis sites and in burn wounds.32,33 Electrotherapy and ionizing radiation have also been suggested as possible triggers.34

Porokeratosis and Malignant Transformation

Keratinocytes underlying the cornoid lamella exhibit varying degrees of dysplasia.2,35 The initial mechanism for malignant transformation would be allelic loss associated with p53 overexpression.36,37 Other proteins, such as psi-3, cytokeratin, filaggrin, and involucrin, may also be involved. UV radiation may act as a trigger by inducing p53 mutations.2

Porokeratosis is considered a premalignant condition, as all its variants have a potential for malignant transformation. The most common cancer is squamous cell carcinoma followed by basal cell carcinoma.35 Malignant lesions are solitary in approximately 2 to 3 cases and are frequently located on non–sun-exposed skin on the extremities; they can appear up to 36 years after onset of porokeratosis.2 The estimated incidence of malignant transformation is 7.5% to 11.%38,39 (Table 1). The risk is greater with larger lesions, as they have a hypertrophic epidermis and more DNA ploidy alterations.40

Table 1.

Clinical and Epidemiological Characteristics of the Various Subtypes of Porokeratosis.

  Frequency  Epidemiology  Triggers  Clinical Manifestations  Associations  Association With Skin Cancer 
DSAP  42% (most common subtype)  Third-fourth decade F>M (1.8:1)  UV radiation  Erythematous skin-colored or hyperpigmented annular papules with a keratotic border, symmetrically distributed on the arms, legs, shoulders, and back    Rare (3%) 
        Generally asymptomatic     
DSP  Rare  Childhood (5–10 years)  Immunosuppression  Same clinical features as DSAP, but affects both sun-exposed and non–sun-exposed areas  Solid organ tumorsa  Rare 
Porokeratosis of Mibelli  35% (second most common subtype)  Childhood  Immunosuppression in adults  Small, asymptomatic or mildly pruritic papules; slow progression to solitary or isolated plaques of several centimeters in diameter, usually on the trunk and/or limbs    8% 
    M>F (2–3:1)         
Linear porokeratosis  13%  Childhood, occasionally adulthood    Similar to DSAP but with a linear distribution following Blaschko lines; may be segmental or generalized    19% 
    F>M (1.6:1)         
EDP  Very rare (about 30 cases described)  Middle age  Hepatotropic viruses, malignancy  Abrupt onset of erythematous papules with keratotic borders and a progressive course; intensely pruritic  Hepatic-digestive and hematological malignancy (one-third of cases)  Rare 
Porokeratosis palmaris et plantaris disseminata  Very rare  Adolescence or early adulthood  UV radiation  Bilateral, symmetric keratotic papules measuring 1–2mm on the palms and/or soles; may be generalized with DSAP-like lesions on the trunk and limbs or affect mucous membranes    10% 
  (<20 reported cases)           
Punctate porokeratosis  Very rare  Adolescence or early adulthood    Keratotic seed-like depressed or spiculated papules measuring 1-2 mm on the palms and soles    Rare 
Porokeratosis ptychotropica  Very rare  Middle age  Trauma, scratching  Progressive verrucous hyperkeratotic plaques on the buttocks (in a butterfly pattern) and in the perianal region;    Rare 
    90% men    Intensely pruritic     
Penoscrotal porokeratosis  Very rare  Third decade  Trauma, scratching  Granular patches and plaques on the shaft of the penis and anterior scrotum; pruritic    Rare 
Follicular porokeratosis  Very rare  All ages    Macules, papules, or annular plaques with erythematous borders mainly affecting the face    Rare 
  (11 cases reported)  M>       

Abbreviations: DSAP, disseminated superficial actinic porokeratosis; DSP, disseminated superficial porokeratosis; EDP, eruptive disseminated porokeratosis; F, female; M, male.


Given the clinical descriptions and photographs, cases of PSD associated with malignancy might actually be EDP.

Source: Kanitakis et al.,1 Sertznig et al.,2 Williams et al.50

Clinical Presentation

Porokeratosis presents as well-delimited papules or erythematous-brownish plaques of varying shapes and sizes with centrifugal growth. The border is formed by a thin keratotic ridge pointing towards the center of the lesion, which can be depressed or slightly atrophic, or, less frequently, hyperkeratotic and hyperpigmented.1,2

An overview of the different clinical variants of porokeratosis, which differ in lesion number, size, shape, and distribution, is given below and summarized in Table 1.

  • a.

    Disseminated Superficial Actinic Porokeratosis

DSAP is the most common form of porokeratosis, accounting for 56% of all clinical variants.4 It is directly related to sun exposure and typically presents in the third or fourth decade of life and is more common in women (female to male [F–M] ratio, 1:8:1). It is characterized by multiple small annular papules (sometimes in their hundreds) that sometimes coalesce into polycyclic plaques. They are distributed symmetrically on the back and the extensor surface of the extremities1,2 (Fig. 1A–B). The face is affected in just 15% of cases.41 DSAP is usually asymptomatic, but it can cause pruritus in up to one-third of patients.1 More than 50% of patients report worsening during the summer or after phototherapy.42

  • b.

    Disseminated Superficial Porokeratosis

Figure 1.

A–B, Disseminated superficial actinic porokeratosis. Multiple well-circumscribed brownish annular plaques with a raised border on the legs. C–, Disseminated superficial porokeratosis. Well-circumscribed brownish plaques with a raised border on the right thigh.


DSP is similar to DSAP, but is not triggered by UV radiation and is characterized by early onset (age 5–10 years).1,2 It has been described in association with congenital LP in an infant and a child of preschool age.43,44

Lesions are observed on both sun-and non-sun-exposed skin, mainly on the trunk and genitals and in acral regions (Fig. 1C–), although the mouth can also be affected.2,45

  • c.

    Porokeratosis of Mibelli

PM is the second most common form of porokeratosis.3 It usually develops in childhood or adolescence, although adult onset has been described; it is more common in male patients (M–F ratio, 2–3:1).46 It presents as one or more annular plaques with an atrophic, or less frequently, hyperkeratotic center. It is unilateral and shows progressive growth. Giant PM lesions can exceed 20 cm and have high malignant potential1,47 (Fig. 3A). PM usually occurs on the trunk or extremities, although acral, facial, genital, scalp, and oral mucosal lesions have been described.1,2 Isolated cases of a possible hyperkeratotic variant consisting of multiple, verrucous lesions on the extremities have been described.48

  • d.

    Linear Porokeratosis

LP is an uncommon variant of porokeratosis that predominantly affects females (F–M ratio, 1.63:1).2 For some authors, rather than a separate entity, LP is a linear form of PM or DSAP.49 It is characterized by multiple papules or hyperkeratotic plaques in a linear distribution on the extremities (Fig. 2A–B). Lesions usually follow a Blaschkoid pattern, although exceptionally they may be segmental or generalized, reflecting genetic mosaicism.50 LP is usually congenital, although adult onset has been described. It may coexist with DSAP, probably as a result of postzygotic mutations causing loss of heterozygosity (type 2 mosaicism).49,51

  • e.

    Eruptive disseminated porokeratosis

Figure 2.

A–B, Linear porokeratosis. Erythematous-brownish plaques with a scaling border and a linear distribution in the right costal region (A) and on the left thigh (B). C–D, Disseminated superficial porokeratosis. Multiple plaques with an annular erythematous hyperkeratotic border on both arms (C) and the left leg (D); the lesions were intensely pruritic.


EDP encompasses eruptive pruritic papular porokeratosis and inflammatory DSP. It is uncommon and is characterized by the abrupt appearance of erythematous and intensely pruritic skin lesions (Fig. 2C–D). Although EPD has not been clearly defined, some authors have subdivided it into paraneoplastic, immunosuppression-related, inflammatory, and other forms. Paraneoplastic variants may resolve on completion of the cancer treatment, while inflammatory variants can resolve spontaneously.52,53 In our review of the literature, we found 30 cases of EPD, most in middle-aged men (range, 13–84 years). Over 50% of patients had had a previous form of porokeratosis (most often DSP). The most characteristic histologic finding was the presence of a cornoid lamella and a dermal inflammatory infiltrate (with a predominant lymphohistiocytic component in 9 cases and a predominant eosinophilic component in 8). Some authors have described an inflammatory infiltrate with CD8+ lymphocytes (CD4+ cells are more common in DSP) and suggested that EPD might represent an immune response mediated by CD8+ lymphocytes against abnormal keratinocyte clones.54,55 The most important clinical aspect of EPD is that almost one-third of patients have a malignancy (mainly of hepatobiliary or hematologic origin).18,21,31,56–60 It is important thus to screen for these diseases in all patients with EPD (Table 2). Viral infection (herpes simplex virus, HCV,57 or hepatitis B virus) has been reported in almost 20% of patients with EDP, which can also affect immunosuppressed patients61 and patients on certain medications.21 In the vast majority of cases (75%), EPD resolves spontaneously within about 6 months (although it can take up to 2 years). Response to topical or systemic treatment is highly variable, and is inexistent or low in most cases.

  • f.

    Porokeratosis Palmaris et Plantaris Disseminata

Table 2.

Cases Described in the Literature of Eruptive Disseminated Porokeratosis Associated With Malignancy.

  Sex/Age, y  Associated Malignancy  Previous Porokeratosis  Histology  Treatment  Outcome 
Levin et al., 199960  M/70  Myelodysplastic syndrome  ND  Cornoid lamella  None  ND 
Kono et al., 200057M/67  HCC associated with HCV infection (2 mo after EPPP)  No  Cornoid lamella  Percutaneous ethanol injection (HCC)  Good response for HCC and cutaneous lesions 
M/62  HCC associated with HCV infection (6 mo after EPPP)  No  Diagnosis of DSPa  Percutaneous ethanol injection (HCC)  Good response for HCC and cutaneous lesions 
F/58  HCC associated with HCV infection (after EPPP)  No  Diagnosis of DSPa  None  ND 
Lee et al., 200658  F/73  Cholangiocarcinoma  No  Cornoid lamella, dyskeratosis  None  The skin lesions increased for the following 6 mo 
Cannavó et al., 200831  F/54  Ovarian adenocarcinoma  No  Cornoid lamella  None  Remission of lesions after 6 cycles of chemotherapy (ovarian adenocarcinoma responded well) 
Choi et al., 200959M/84  Colorectal carcinoma (6 y after onset)  Yes, DSP  Cornoid lamella, dermal infiltrate with eosinophils and lymphocytes  Topical CSs and antihistamines  Good response after 1 mo 
          Spontaneous regression after 4 mo 
Schena et al., 201056  F/77  Pancreatic cancer  No  Cornoid lamella, dyskeratosis, lymphohistiocytic infiltrate  ND  Died after 2 wk 
Pini et al., 201218M/13  Acute lymphoblastic leukemia (allogenic transplant 1 y before EPPP)  ND  Cornoid lamella, dyskeratosis Dermal lymphocytic infiltrate  Topical urea  No response 
          Spontaneous resolution on interruption of immunosuppression 
Mangas et al., 201821F/62  Metastatic breast cancer (treatment with trastuzumab and exemestane)  ND  Cornoid lamella, hypogranulosis  Topical betamethasone and salicylic acid  Improvement of symptoms 
          Persistence of skin lesions 

Abbreviations: CSs, corticosteroids; DSAP, disseminated superficial actinic porokeratosis; DSP, disseminated superficial porokeratosis; EPPP, eruptive pruritic papular porokeratosis; F, female; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; M, male; ND, not described.


Histologic characteristics not specified in original description.

PPPD is another uncommon variant of porokeratosis, with fewer than 20 cases described in the literature. Most cases are familial and are inherited in an autosomal dominant fashion. PPPD usually starts in adolescence and mainly affects males (M-F ratio, 2:1).62 It is clinically similar to DSP, with bilateral, symmetric keratotic papules measuring 1 to 2mm. In most cases it starts on the palms and soles and then spreads to the rest of the body after several months or years.62,63 There have, however, been anecdotal cases of lesions starting on the trunk and extremities and then spreading to the palms and soles.64 It may worsen during the summer.

  • g.

    Punctate Porokeratosis

PP has been described by some authors as a subtype of PPPD.65 It starts in adolescence or young adulthood and is characterized by multiple seed-like keratotic papules on the palms and soles. These papules measure 1 to 2mm and may be depressed (pits) or raised (spiculated). PP frequently occurs in association with PM or LP.65,66

  • h.

    Genitogluteal Porokeratosis

All variants of generalized porokeratosis can affect the genitals and gluteal region, but there have been few reports of exclusive genitogluteal involvement.67 Three clinical variants have been described:

  • 1.

    Classic porokeratosis in the genital region. Genital porokeratosis affects middle-aged adults and has a predilection for men. It has been suggested that it may be more common in Asians and Afroamericans.68,69 Friction and scratching may be determining factors. It manifests as intensely pruritic annular plaques with an atrophic center on the scrotum, penis, buttocks, or proximal thigh.68

  • 2.

    Porokeratosis ptychotropica. The word ptychotropica comes from the Greek words ptyhce, meaning fold, and trope, meaning turn.70 It is a very rare variant of porokeratosis, with fewer than 30 cases described in the literature. It affects middle-aged adults (90% men).71 It is characterized by thick, pruritic, erythematous-brownish, verrucous plaques that exhibit slow, progressive growth and affect the perianal region, the buttocks, and the intergluteal cleft, forming a butterfly-wing pattern and satellite lesions (Fig. 3B). It can also affect the genitals.68 Diagnostic delay is common as the condition is confused with eczema, genital warts, or mycosis.71 It can be differentiated histologically by the presence of multiple cornoid lamellae throughout the lesion and not just at the border. Amyloid deposits may also be observed in the papillary dermis.72 Infectious agents have not been demonstrated in lesions and there appears to be no link to human papillomavirus infection.73

    Figure 3.

    A, Porokeratosis of Mibelli. Round, erythematous plaque measuring 4cm with a raised hyperkeratotic border on the left knee. Diagnosis was confirmed by histology. B, Porokeratosis ptychotropica. Multiple coalescent erythematous scaling plaques with a hyperkeratotic edge in the perianal area and on the right buttock.

  • 3.

    Penoscrotal porokeratosis. This variant has been described in patients in their third decade of life and is characterized by granular plaques on the shaft of the penis and the anterior scrotum. It is intensely pruritic.68,74 As with porokeratosis ptychotropica, multiple cornoid lamellae are observed during histologic examination.74

  • i.

    Follicular Porokeratosis

Follicular porokeratosis was described for the first time a decade ago,75 and just 11 cases have been reported. It can occur at all ages and appears to be slightly more common in men.76 It manifests as macules-papules or annular plaques with keratotic borders. It mainly affects the face, but may be observed on the trunk and extremities.77 The characteristic histologic finding is a cornoid lamella arising from dilated follicles.75,76

  • j.

    Other Variants

There have been isolated reports of pustular,78 ulcerative,79 bullous,80 and reticulated81 porokeratosis, prurigo nodularis-like lesions82 and seborrheic keratosis-like porokeratosis.83

One recent report described porokeratoma, a porokeratotic acanthoma with multiple cornoid lamellae. This variant manifests as one or more verrucous lesions on the extremities, trunk, or buttocks.84 Some authors see it as a variant of hyperkeratotic porokeratosis, while others believe it to be a separate entity.85


  • a.

    Clinical Diagnosis

The diagnosis of porokeratosis is often exclusively clinical, with skin biopsy reserved for atypical or doubtful cases.

  • b.

    Dermoscopy and Other Imaging Techniques

Dermoscopic findings in the varying clinical forms of porokeratosis include a hyperkeratotic white, yellow, or brown peripheral edge (double-track sign), a homogeneous central area that may have a scar-like appearance or contain brown dots or globules or vascular structures, such as irregular globular and linear vessels crossing the lesion86,87 (Fig. 4A–B). Ink-enhanced dermoscopy can be useful, as when the lesion is cleaned with alcohol 70%, the ink remains at the ridge-like cornoid lamella, differentiating it from other skin conditions.88

Figure 4.

Porokeratosis. A–B, Dermoscopy. Erythematous brownish lesion without clearly defined structures and with a brownish annular border (A). Lesion with structureless white areas and dotted vessels and a hyperkeratotic annular border. Note the double-track sign (B) (Gen Dermlite DL200, ×8). C–D. Histology. Epidermal invagination with a parakeratotic column (cornoid lamella) (arrow)) (hematoxylin–eosin, original magnification ×40) (C). Cornoid lamella (D). Note the loss of the granular layer underlying the parakeratotic column (arrow) and the keratinocytes in the stratum spinosum (hematoxylin–eosin, original magnification ×200). Cornoid lamella (arrow) (hematoxylin–eosin, ×100).


The cornoid lamella is discerned as a bright parakeratotic structure without an underlying granular layer by reflectance confocal microscopy.87 This structure can also be visualized by optical coherence tomography.2

  • c.


Biopsy of the border of a porokeratotic lesion shows a well-delimited column of parakeratotic cells (cornoid lamella). There may also be hypogranulosis or agranulosis in this area and occasional dyskeratotic cells or vacuolated keratinocytes (Fig. 4C–D). There have been isolated reports of eosinophilic spongiosis. Additional findings include a small perivascular inflammatory infiltrate composed mainly of CD4+ lymphocytes.1,2 A CD8+ lymphocytic infiltrate has been observed in EDP.55 Finally, mild orthokeratotic hyperkeratosis can be seen in the center of lesions.1

Differential Diagnosis

Multiple entities should be considered in the differential diagnosis of the clinical variants of porokeratosis (Table 3).1,2,46,66,89 The most characteristic histologic feature of porokeratosis is the cornoid lamella.

Table 3.

Differential Diagnosis for Porokeratosis.

Subtype of Porokeratosis  Differential Diagnosis 
DSP and DSAP  Actinic keratosis, seborrheic keratosis, lichen planus, tinea corporis, psoriasis, nummular eczema, and pink pityriasis 
PM  Bowen disease, granuloma, palmoplantar/circumscribed plantar hypokeratosis, lichen simplex chronicus, tinea corporis, sarcoidosis 
LP  Linear warts, lichen striatus, linear verrucous epidermal nevus, linear Darier disease, and porokeratotic eccrine ostial and dermal duct nevus 
PPPD and PP  Hereditary punctate palmoplantar keratoderma, spiny keratoderma, Gorlin syndrome, Darier disease, arsenical keratosis, and palmoplantar lichen nitidus 
Porokeratosis ptychotropica  Psoriasis, enteropathic acrodermatitis, and necrolytic migratory erythema 

Abbreviations: DASP, disseminated actinic superficial porokeratosis; DSP, disseminated superficial porokeratosis; LP, linear porokeratosis; PM, porokeratosis of Mibelli; PP, porokeratosis punctata; PPPD, porokeratosis palmaris et plantaris disseminata.

Source: Kanitakis et al.,1 Sertznig et al.,2 Ferreira et al.,46 Teixeira et al.,66 Elfatoiki et al.89

The cornoid lamella, however, can also be observed in verruca vulgaris, actinic keratosis, certain ichthyoses, and nevoid hyperkeratosis, but in porokeratosis, the granular layer underlying the parakeratotic column is usually absent.2 A cornoid lamella may also be observed in keratosis punctata, an inheritable condition, and spiny keratoderma, making distinction from PPPD and PP difficult. Nonetheless, dyskeratotic cells or vacuolated cells are usually observed in PPPD and PP.66 In addition, multiple cornoid lamellae are observed in porokeratoma and genitogluteal porokeratosis.71,84


Porokeratosis tends to follow a chronic course and is often refractory to treatment, with just 16% of patients achieving complete response.4 A watch-and-wait approach—with adequate use of sun protection and emollients and regular long-term follow-up—is a valid option for asymptomatic patients or patients (Fig. 5). Follow-up is particularly important considering the risk of malignant transformation, particularly in the case of PM, LP, PPPD, and large lesions.1 An exhaustive search for underlying malignancy, particularly of hepatobiliopancreatic or hematologic origin, is warranted in patients with EDP.52

Figure 5.

Treatment algorithm for porokeratosis. 5-FU indicates 5-fluorouracil; DSAP, disseminated actinic superficial porokeratosis; DSP, disseminated superficial porokeratosis; EDP, eruptive disseminated porokeratosis; GRT, Grenz ray therapy; LP, linear porokeratosis; PDT, photodynamic therapy: PM, porokeratosis of Mibelli; PDT, photodynamic therapy; PPPD, porokeratosis palmaris et plantaris disseminata.

a Histology only in atypical or doubtful cases.

b Mainly of hepatobiliopancreatic and hematologic origin. Order complete blood count, liver profile, lactate dehydrogenase, and computed tomography of the chest and abdomen.

c Rule out skin cancer (squamous and basal cell carcinoma).


No controlled clinical trials have evaluated the efficacy of the different treatment options available for symptomatic porokeratosis, and existing recommendations are based mainly on case reports, small series with fewer than 20 patients, and 2 systematic reviews.90,91Table 4 summarizes the different topical, systemic, and physical treatment options available, together with information on level of evidence. Cryotherapy,92, curettage, electrosurgery, photodynamic therapy, and surgical excision are possibilities for smaller, symptomatic lesions, but there is a risk of postinflammatory hyperpigmentation or scarring.90,93 Topical vitamin D analogues and retinoids, 5-fluorouracil, and imiquimod 5% may be indicated for larger or multiple (but localized) lesions.90,94 Imiquimod appears to be the best option for PM.90 Topical or oral retinoids could be used as first-line treatment for LP,90 while photodynamic therapy could be recommended as first- or second-line treatment for localized forms of porokeratosis.

Table 4.

Treatment of Porokeratosis and Clinical Response.

Administration Route  Drug  Study Type  Type of Porokeratosis  Response to Treatment 
TopicalSalicylic acid  3 case reports  2 cases of genitogluteal porokeratosis and 1 of plantar PP  Complete response in genitogluteal porokeratosis with topical corticosteroids and in PP with topical 5-fluorouracil 
Corticosteroids  4 case reports  1 case each of EDP and PM and 2 cases of genitogluteal porokeratosis  Partial response in EDP (antihistamines also used), no response in PM, and control of symptoms in genitogluteal porokeratosis (salicylic acid also used) 
5-Fluorouracil  6 case reports  3 cases of PM and 1 case each of DSAP, PP, and seborrheic keratosis-like porokeratosis  Complete response in 1 case of PM (imiquimod also used) and partial response in other 5 cases 
Imiquimod 5%  11 case reports  9 cases of PM, 1 of DSAP, and 1 of LP  Complete resolution in all cases 
Vitamin D3 analogues (calcipotriol, tacalcitol)  8 case reports  8 cases of DSAP, 1 of LP, and 1 of seborrheic keratosis-like porokeratosis  3 complete responses, 6 partial responses, and 1 no response 
  1 case series (n=2)     
Diclofenac 3%  Prospective multicenter study (n=17)  25 cases of DSAP and 1 of genitogluteal porokeratosis  Partial improvement in 46% of cases 
  1 case series (n=8)     
  1 case report     
Retinoids  5 case reports  2 cases each of LP and PM, 1 case of DSAP and LP, and 1 case each of DSAP, FP, and “zosteriform porokeratosis”  4 complete responses, 2 mild improvements 
  1 case series (n=3)     
Ingenol mebutate 0.05%  1 case report  PM  Partial response 
Cantharidin  1 case series (n=2)  2 cases of PM  Complete response 
Tacrolimus 0.1%  1 case report  LP  Complete response (betamethasone ointment also used) 
SystemicRetinoids (acitretin, etretinate, isotretinoin)  10 case reports  3 cases each of LP and facial porokeratosis, 2 cases of DPPP, and 1 case each of hyperkeratotic porokeratosis and genitogluteal porokeratosis  6 complete responses and 7 partial responses 
  1 case series (n=3)  1 case each of PSD, 1 porokeratosis ptychotropica, and PM   
Palifermin  1 case report  DSAP  Complete response 
Corticosteroids (prednisolone, dexamethasone)  2 case reports  1 cases of DSP and 1 of PM  1 complete response and 1 partial response 
Ciclosporin  1 case report  EDP  Near-complete response 
PhysicalCryotherapy  3 case reports  10 cases of PM and 1 each of DSAP, LP, and genitogluteal porokeratosis  Complete response in all cases 
  2 case series (2 and 8 patients, respectively)     
Shaving, electrodessication, curettage  2 case reports  1 case of PM and 1 of porokeratosis ptychotropica  Complete response in both cases 
Dermabrasion  2 case reports  1 case of PM and 1 of LP  Complete response in both cases 
Surgical aspiration with ultrasound  1 case report  Vulvar porokeratosis  Partial response 
Conventional PDT (methyl aminolevulinate, aminolevulinic acid, hypericin) and daylight PDT  7 case reports  31 cases of DSAP,a 5 of PM, 4 of LP, and 2 of porokeratosis ptychotropica93  Complete response in 31% of patients and partial response in 35% 
  Prospective multicenter study (n=16)     
  7 case series (1 with 6 patients, 1 with 3, and 5 with 2a   
Laser therapy: carbon dioxide, Q-switched erbium: YAG, Nd:YAG, fractional photothermolysis, PDL  10 case reports  7 cases of DSAP, 3 of PM, and 1 each of porokeratosis ptychotropica, facial porokeratosis, and reticulated porokeratosis  7 complete responses, 4 partial responses, and 2 no responses 
  1 case series (n=3)     
Intense pulsed light  1 case series (n=10)  LP  Just 1 case of partial improvement 
Grenz ray therapy  1 case report  Bullous DSAP  Complete response in all cases 
  1 retrospective study (n=8)101  DSAP   

Abbreviations: DSAP, disseminated actinic superficial porokeratosis; DSP, disseminated superficial porokeratosis; EDP, eruptive disseminated porokeratosis; FP, follicular porokeratosis; LP, linear porokeratosis; PDL, pulsed dye laser; PDT, photodynamic therapy; PM, porokeratosis of Mibelli; PP, porokeratosis punctata; PPPD, porokeratosis palmaris et plantaris disseminata


Two of the cases are from Ferrer et al.99 and were treated with daylight PDT, with good response.

Source: Weidner et al.,90 Aird et al.,91 Ferrer et al.,99 Fustà-Novell et al.,93 Ramelyte et al.101

In the case of disseminated disease, such as DSAP or DSP, there have been multiple case reports describing good response to vitamin D analogues, with very few or no adverse effects.95 Some authors therefore recommend this option as a first-line treatment for disseminated lesions.90 In a prospective study of 17 adults with DSAP, the largest conducted to date in patients with porokeratosis, topical diclofenac 3% applied for a period of 3 to 6 months prevented lesion progression in over 50% of cases.96 However, in another series of 8 patients also treated with topical diclofenac 3%, just 2 patients responded (partial response).97 Conventional or daylight photodynamic therapy is among the most studied treatments (approximately 42 patients). Response rates ranged from 31% for partial response to 35% for complete response (with the best results observed for DSAP).90,91,98,99 This treatment can, however, cause considerable adverse effects.91 Various forms of laser therapy have been used in a small number of patients (around 13) and have shown promising results, with good response rates and few adverse effects.91 While effective in numerous skin disorders, intense pulsed light was not found to be beneficial in a series of 10 patients with DSP (1 complete response).100 Another form of physical therapy is Grenz ray therapy (GRT). In one retrospective study, all 8 patients achieved complete response with 6 to 10 sessions of GRT at a total dose of 28 to 52 Gy. The treatment had to be interrupted in just 1 patient (due to adverse effects) and another experienced recurrence. None of the patients developed skin carcinoma on the irradiated surface during clinical follow-up.101 Oral retinoids have been used in 13 patients (6 complete and 7 partial responses),102 while systemic corticosteroids have been used in 2 patients (1 complete response)2,90 and ciclosporin in 1 (a near-complete response).103


Porokeratosis is a rare skin disorder with a wide spectrum of clinical variants with which clinicians should be familiar in order to avoid errors and diagnostic delay. Long-term follow-up is important to check for early signs of skin malignancy, a risk that exists in all variants of porokeratosis. Solid organ or hematologic malignancies should be ruled out in patients with eruptive disease. The treatment of porokeratosis is complex and often unsatisfactory, and a watch-and-wait approach may be an option to take into account.


No funding was received for this study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

J. Kanitakis.
Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features.
Eur J Dermatol, 24 (2014), pp. 533-544
P. Sertznig, V. von Felbert, M. Megahed.
Porokeratosis: present concepts.
J Eur Acad Dermatol Venereol, 26 (2012), pp. 404-412
Y.H. Leow, Y.H. Soon, S.N. Tham.
A report of 31 cases of porokeratosis at the National Skin Centre.
Ann Acad Med Singapore, 25 (1996), pp. 837-841
L.S. Tan, W.S. Chong.
Porokeratosis in Singapore: an Asian perspective.
Aust J Dermatol, 53 (2012), pp. e40-e44
C.S. Shen, K. Tabata, M. Matsuki, T. Goto, T. Yokochi, K. Yamanishi.
Premature apoptosis of keratinocytes and the dysregulation of keratinization in porokeratosis.
Br J Dermatol, 147 (2002), pp. 498-502
J.H. Xia, Y.F. Yang, H. Deng, B.S. Tang, D.S. Tang, Y.G. He, et al.
Identification of a locus for disseminated superficial actinic porokeratosis at chromosome 12q23.2–24.1.
J Invest Dermatol, 114 (2000), pp. 1071-1074
K. Xia, H. Deng, J.H. Xia, D. Zheng, H.L. Zhang, C.Y. Lu, et al.
A novel locus (DSAP2) for disseminated superficial actinic porokeratosis maps to chromosome 15q25.1–26.1.
Br J Dermatol, 147 (2002), pp. 650-654
S. Wei, S. Yang, D. Lin, M. Li, X. Zhang, L. Bu, et al.
A novel locus for disseminated superficial porokeratosis maps to chromosome 18p11.3.
J Invest Dermatol, 123 (2004), pp. 872-875
P. Liu, S. Zhang, Q. Yao, X. Liu, X. Wang, C. Huang, et al.
Identification of a genetic locus for autosomal dominant disseminated superficial actinic porokeratosis on chromosome 1p31.3–p31.1.
Hum Genet, 123 (2008), pp. 507-513
J. Luan, Z. Niu, J. Zhang, M.E. Crosby, Z. Zhang, X. Chu, et al.
A novel locus for disseminated superficial actinic porokeratosis maps to chromosome 16q24.1–24.3.
Hum Genet, 129 (2011), pp. 329-334
S.C. Wei, S. Yang, M. Li, Y.X. Song, X.Q. Zhang, L. Bu, et al.
Identification of a locus for porokeratosis palmaris et plantaris disseminata to a 6.9-cM region at chromosome 12q24.1–24.2.
Br J Dermatol, 149 (2003), pp. 261-267
R. Happle.
Porokeratosis palmaris, plantaris et disseminata vs porokeratosis of Mibelli.
Br J Dermatol, 166 (2012), pp. 681-682
Y. Leng, L. Yan, H. Feng, C. Chen, S. Wang, Y. Luo, et al.
Mutations in mevalonate pathway genes in patients with familial or sporadic porokeratosis.
J Dermatol, 45 (2018), pp. 862-866
S.Q. Zhang, T. Jiang, M. Li, X. Zhang, Y.Q. Ren, S.C. Wei, et al.
Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis.
Nat Genet, 44 (2012), pp. 1156-1160
X. Fu, T. Liu, Z. Wang, G. Zhou, M. Yu, X. Lu, et al.
Two novel SSH1 mutations in Chinese patients with disseminated superficial actinic porokeratosis and immunohistochemical analysis of anti-slingshot homolog 1 antibody in one typical patient.
J Eur Acad Dermatol Venereol, 33 (2019), pp. e486-e488
J. Murase, A.C. Gilliam.
Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: update on the genetics and clinical expression of porokeratosis.
J Am Acad Dermatol, 63 (2010), pp. 886-891
M. Marque, L. Meunier.
Ann Dermatol Venereol, 139 (2012), pp. 668-676
M. Pini, Y. Balice, S. Tavecchio, D. Crippa.
Eruptive disseminated porokeratosis following bone marrow transplantation for acute lymphoblastic leukemia in a child.
J Dermatol, 39 (2012), pp. 403-404
Y.W. Han, Y.J. Kim, H.O. Kim, Y.M. Park.
Clinical study of porokeratosis associated with immunosuppressive therapy in renal transplant recipients.
Ann Dermatol, 20 (2008), pp. 167-171
J.M.R. Goulding, J.K. Teoh, R.A. Carr, F. Humphreys, B.C. Gee.
Eruptive disseminated superficial porokeratosis with rapid resolution: a drug-induced phenomenon?.
Clin Exp Dermatol, 34 (2009), pp. 895-897
C. Mangas, V. Espeli, R. Blum.
A case of eruptive disseminated porokeratosis in a cancer patient after trastuzumab and exemestane treatment: cancer related or drug induced phenomenon?.
Actas Dermosifiliogr, 109 (2018), pp. 559-560
L. Stewart, A. Howat, I. Coulson.
Disseminated superficial porokeratosis secondary to immunosuppression induced by etanercept for extensive psoriasis.
Arch Dermatol, 146 (2010), pp. 1193-1194
J.A. Brauer, R. Mandal, R. Walters, G. Solomon, R.V. Kundu, B.E. Strober.
Disseminated superficial porokeratosis.
Dermatol Online J, 16 (2010), pp. 20
A.C. Esser, M.R. Pittelkow, H.W. Randle.
Human papillomavirus isolated from transplant-associated porokeratoses of Mibelli responsive to topical 5% imiquimod cream.
Dermatol Surg, 32 (2006), pp. 858-861
C.A. Morton, D. Shuttleworth, W.S. Douglas.
Porokeratosis and Crohn's disease.
J Am Acad Dermatol, 32 (1995), pp. 894-897
E. Dippel, N. Haas, B.M. Czarnetzki.
Porokeratosis of Mibelli associated with active chronic hepatitis and vitiligo.
Acta Derm Venereol, 74 (1994), pp. 463-464
A.G. Rao, T.S. Lakshmi, S. Haritha.
Disseminated superficial porokeratosis.
Indian J Dermatol Venereol Leprol, 68 (2002), pp. 284-285
A.C. Tappel, N. Tiwari, B. Zlotoff.
Linear porokeratosis associated with Bardet-Biedl syndrome: a case report.
Pediatr Dermatol, 36 (2019), pp. 346-348
S.K. Ghosh, D. Bandyopadhyay, G. Chatterjee, A.P. Ghosh.
Co-localization of lichen planus and porokeratosis of Mibelli.
Indian J Dermatol Venereol Leprol, 75 (2009), pp. 532-534
D. Schena, A. Papagrigoraki, A. Frigo, G. Girolomoni.
Eruptive disseminated porokeratosis associated with internal malignancies: a case report.
Cutis, 85 (2010), pp. 156-159
S.P. Cannavó, F. Borgia, B. Adamo, B. Guarneri.
Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: coincidental association or true paraneoplastic syndrome?.
J Am Acad Dermatol, 58 (2008), pp. 657-660
A. Nakazawa, I. Matsuo, M. Ohkido.
Porokeratosis localized to the access region for hemodialysis.
J Am Acad Dermatol, 25 (1991), pp. 338-340
M.P. Nova, L.J. Goldberg, T. Mattison, A. Halperin.
Porokeratosis arising in a burn scar.
J Am Acad Dermatol, 25 (1991), pp. 354-356
A.J. James, L.E. Clarke, R. Elenitsas, K. Katz.
Segmental porokeratosis after radiation therapy for follicular lymphoma.
J Am Acad Dermatol, 58 (2008), pp. S49-S50
J. Schierbeck, T. Vestergaard, A. Bygum.
Skin cancer associated genodermatoses: a literature review.
Acta Derm Venereol, 99 (2019), pp. 360-369
R. Happle.
Cancer proneness of linear porokeratosis may be explained by allelic loss.
Dermatoly, 195 (1997), pp. 20-25
I. Arranz-Salas, A. Sanz-Trelles, D.B. Ojeda.
p53 alterations in porokeratosis.
J Cutan Pathol, 30 (2003), pp. 455-458
F. Otsuka, T. Someya, Y. Ishibashi.
Porokeratosis and malignant skin tumors.
J Cancer Res Clin Oncol, 117 (1991), pp. 55-60
M. Sasson, A.D. Krain.
Porokeratosis and cutaneous malignancy. A review.
Dermatol Surg, 22 (1996), pp. 339-342
F. Otsuka, Y. Umebayashi, S. Watanabe, M. Kawashima, S. Hamanaka.
Porokeratosis large skin lesions are susceptible to skin cancer development: histological and cytological explanation for the susceptibility.
J Cancer Res Clin Oncol, 119 (1993), pp. 395-400
H. Riad, K. Mansour, H.A. Sada, S.A. Shaika, H.A. Ansari, H.A. Mohannadi.
Disseminated superficial actinic porokeratosis on the face treated with imiquimod 5% cream.
Case Rep Dermatol, 5 (2013), pp. 283-289
A.L. Allen, D.A. Glaser.
Disseminated superficial actinic porokeratosis associated with topical PUVA.
J Am Acad Dermatol, 43 (2000), pp. 720-722
E. Cho, Y.B. Lee, H.J. Park, B.K. Cho.
Coexistence of congenital linear porokeratosis and disseminated superficial porokeratosis.
Australas J Dermatol, 53 (2012), pp. e30-e31
D.H. Suh, H.S. Lee, S.D. Kim, K.H. Cho, K.H. Kim, K.C. Park.
Coexistence of disseminated superficial porokeratosis in childhood with congenital linear porokeratosis.
Pediatr Dermatol, 17 (2000), pp. 466-468
R. Bhatia, V. Gupta, N. Khanna.
Oral involvement in disseminated superficial porokeratosis.
Indian J Dermatol Venereol Leprol, 83 (2017), pp. 244-246
F.R. Ferreira, L.D. Nogueira Santos, F.A. Nogueira Mendes Tagliarini, M.L. de Alvarenga Lira.
Porokeratosis of Mibelli – literature review and a case report.
An Bras Dermatol, 88 (2013), pp. 179-182
L. Vence, C.B. Thompson, J.P. Callen, T.S. Brown.
Giant porokeratosis with malignant transformation to squamous cell carcinoma.
Dermatol Surg, 44 (2018), pp. 580-581
H.J. Yu, K.T. Park, D.H. Oh, J.S. Kim, Y.W. Park.
A case of the hyperkeratotic variant of porokeratosis Mibelli.
J Dermatol, 33 (2006), pp. 291-294
N. Schwarz, V. Stadie, B. Kreft, R. Happle, W.Ch. Marsch, E. Fiedler.
Systematized linear porokeratosis: concept of type 2 segmental manifestation implies an increased cancer risk.
J Dermatol, 39 (2012), pp. 953-954
G.M. Williams, E.P. Fillman.
StatPearls Publishing, (2018),
P. Freyschmidt-Paul, R. Hoffmann, A. König, R. Happle.
Linear porokeratosis superimposed on disseminated superficial actinic porokeratosis: report of two cases exemplifying the concept of type 2 segmental manifestation of autosomal dominant skin disorders.
J Am Acad Dermatol, 41 (1999), pp. 644-647
I. Shoimer, L.H. Robertson, G. Storwick, R.M. Haber.
Eruptive disseminated porokeratosis: a new classification system.
J Am Acad Dermatol, 71 (2014), pp. 398-400
T. Kanzaki, N. Miwa, T. Kobayashi, S. Ogawa.
Eruptive pruritic papular porokeratosis.
M. Tanaka, T. Terui, K. Kudo, H. Tagami.
Inflammatory disseminated superficial porokeratosis followed by regression.
Br J Dermatol, 132 (1995), pp. 153-155
T. Kanekura, N. Yoshii.
Eruptive pruritic papular porokeratosis: a pruritic variant of porokeratosis.
J Dermatol, 33 (2006), pp. 813-816
D. Schena, A. Papagrigoraki, A. Frigo, G. Girolomoni.
Eruptive disseminated porokeratosis associated with internal malignancies: a case report.
Cutis, 85 (2010), pp. 156-159
T. Kono, H. Kobayashi, M. Ishii, S. Nishiguchi, S. Taniguchi.
Synchronous development of disseminated superficial porokeratosis and hepatitis C virus-related hepatocellular carcinoma.
J Am Acad Dermatol, 43 (2000), pp. 966-968
H.W. Lee, S.H. Oh, J.C. Choi, S.E. Chang, M.W. Lee, J.H. Choi, et al.
Disseminated superficial porokeratosis in a patient with cholangiocarcinoma.
J Am Acad Dermatol, 54 (2006), pp. S56-S58
K.H. Choi, T.Y. Kim.
A case of inflammatory disseminated superficial porokeratosis in a colon cancer patient.
Ann Dermatol, 21 (2009), pp. 150-153
R.M. Levin, W.R. Heymann.
Superficial disseminate porokeratosis in a patient with myelodysplastic syndrome.
Int J Dermatol, 38 (1999), pp. 138-139
M. Pini, Y. Balice, S. Tavecchio, D. Crippa.
Eruptive disseminated porokeratosis following bone marrow transplantation for acute lymphoblastic leukemia in a child.
J Dermatol, 39 (2012), pp. 403-404
R. Irisawa, M. Yamazaki, T. Yamamoto, R. Tsuboi.
A case of porokeratosis plantaris palmaris et disseminata and literature review.
Dermatol Online J, 18 (2012), pp. 5
R. Hartman, R. Mandal, M. Sanchez, J.A. Stein.
Porokeratosis plantaris, palmaris, et disseminata.
Dermatol Online J, 16 (2010), pp. 22
K. Chinmay, S. Prodip, B. Sabyasachi, B. Rabindranath, D. Pallab.
Porokeratosis palmaris et plantaris disseminata – a rare entity.
J Pak Assoc Dermatol, 26 (2017), pp. 371-374
P. Lanka, L.R. Lanka, D. Manivachagam.
Punctate porokeratosis palmaris et plantaris.
Indian J Dermatol, 60 (2015), pp. 284-286
V.B. Teixeira, J.P. Reis, R. Vieira, Ó. Tellechea, A. Figueiredo.
Unilateral punctate porokeratosis – case report.
An Bras Dermatol, 88 (2013), pp. 441-443
S.S. Kumar, S. Lee.
Genitogluteal porokeratosis: an unusual clinical presentation.
Australas J Dermatol, 53 (2012), pp. e36-e39
R. Joshi, K. Minni.
Genitogluteal porokeratosis: a clinical review.
Clin Cosmet Investig Dermatol, 11 (2018), pp. 219-229
T.J. Chen, Y.C. Chou, C.H. Chen, T.T. Kuo, H.S. Hong.
Genital porokeratosis: a series of 10 patients and review of the literature.
Br J Dermatol, 155 (2006), pp. 325-329
G.P. Lucker, R. Happle, P.M. Steijlen.
An unusual case of porokeratosis involving the natal cleft: porokeratosis ptychotropica?.
Br J Dermatol, 132 (1995), pp. 150-151
R.H. Takiguchi, K.P. White, C.R. White Jr., E.L. Simpson.
Verrucous porokeratosis of the gluteal cleft (porokeratosis ptychotropica): a rare disorder easily misdiagnosed.
J Cutan Pathol, 37 (2010), pp. 802-807
T. Uenishi, K. Teramura, M. Kitamura, N. Fujii, G. Nakanishi, T. Tanaka, et al.
Hyperkeratotic variant of porokeratosis Mibelli with dermal amyloid deposits.
J Dermatol, 37 (2010), pp. 475-479
J. Contreras-Ruiz, S. Toussaint-Caire, P. Torres-Camacho, V.B. Villa-Castro.
Porokeratosis ptychotropica: a diagnostic and therapeutic challenge.
J Eur Acad Dermatol Venereol, 32 (2018), pp. e114-e115
R. Joshi, Y. Jadhav.
Penoscrotal porokeratosis: a distinct entity.
Indian Dermatol Online J, 6 (2015), pp. 339-341
M. Pongpudpunth, J. Farber, M. Mahalingam.
Follicular porokeratosis: distinct clinical entity or histologic variant?.
J Cutan Pathol, 36 (2009), pp. 1195-1199
R. Sun, H. Chen, S. Lian, W. Zhu.
Follicular porokeratosis: a case study and literature review.
Eur J Dermatol, 27 (2017), pp. 332-334
J. Kim, B.A. Wood, N.T. Harvey.
Follicular porokeratosis of the nose: two further cases of an emerging variant of porokeratosis.
Pathology, 47 (2015), pp. 482-485
D.D. Miller, B.S. Ruben.
Pustular porokeratosis.
J Cutan Pathol, 36 (2009), pp. 1191-1193
T. Watanabe, T. Murakami, H. Okochi, K. Kikuchi, M. Furue.
Ulcerative porokeratosis.
Dermatology, 196 (1998), pp. 256-259
C. Ricci, A. Rosset, R.G. Panizzon.
Bullous and pruritic variant of disseminated superficial actinic porokeratosis: successful treatment with grenz rays.
Dermatology, 199 (1999), pp. 328-331
R.J. Helfman, E.G. Poulos.
Reticulated porokeratosis. A unique variant of porokeratosis.
Arch Dermatol, 121 (1985), pp. 1542-1543
B.D. Kang, Y.C. Kye, S.N. Kim.
Disseminated superficial actinic porokeratosis with both typical and prurigo nodularis-like lesions.
P. Asawanonda, N. Noppakun, P. Huiprasert.
Seborrheic keratosis-like porokeratosis: a case report.
Dermatol Online J, 11 (2005), pp. 18
P. Caseiro Silverio, X.C. Pham, G. Kaya.
Porokeratoma: a possible association with human papillomavirus infection.
Dermatopathology (Basel), 2 (2015), pp. 43-45
A. Batalla, E. Rosón, C. De la Torre.
Porokeratoma: a different entity or a variant of verrucous (hyperkeratotic) porokeratosis?.
Indian J Dermatol, 58 (2013), pp. 158
A. Nicola, J. Magliano.
Dermoscopy of disseminated superficial actinic porokeratosis.
Actas Dermosifiliogr, 108 (2017), pp. e33-e37
E. Moscarella, C. Longo, I. Zalaudek, G. Argenziano, S. Piana, A. Lallas.
Dermoscopy and confocal microscopy clues in the diagnosis of psoriasis and porokeratosis.
J Am Acad Dermatol, 69 (2013), pp. e231-e233
C. Navarrete-Dechent, P. Uribe, A. Marghoob.
Ink-enhanced dermoscopy is a useful tool to differentiate acquired solitary plaque porokeratosis from other scaly lesions.
J Am Acad Dermatol, 80 (2019), pp. e137-e138
F.Z. Elfatoiki, W. Soussi, S. Chiheb, L. Jabri, H. Benchikhi.
Cutaneous sarcoidosis simulating porokeratosis of Mibelli.
Pan Afr Med J, 20 (2015), pp. 195
T. Weidner, T. Illing, D. Miguel, P. Elsner.
Treatment of porokeratosis: a systematic review.
Am J Clin Dermatol, 18 (2017), pp. 435-449
G.A. Aird, J.L. Sitenga, A.H. Nguyen, A. Vaudreuil, C.J. Huerter.
Light and laser treatment modalities for disseminated superficial actinic porokeratosis: a systematic review.
Lasers Med Sci, 32 (2017), pp. 945-952
T. Dereli, S. Ozyurt, G. Ozturk.
Porokeratosis of Mibelli: successful treatment with cryosurgery.
J Dermatol, 31 (2004), pp. 223-227
X. Fustà-Novell, S. Podlipnik, A. Combalia, D. Morgado-Carrasco, J. Ferrando, J.M. Mascaró Jr., et al.
Porokeratosis ptychotropica responding to photodynamic therapy: an alternative treatment for a refractory disease.
Photodermatol Photoimmunol Photomed, 33 (2017), pp. 271-274
B. Gajic, K. Tang, M. Whitfeld.
Porokeratosis of Mibelli: involution and resolution with 5% imiquimod cream.
Australas J Dermatol, 52 (2011), pp. 301-303
P.V. Harrison, N. Stollery.
Disseminated superficial actinic porokeratosis responding to calcipotriol.
Clin Exp Dermatol, 19 (1994), pp. 95
S. Marks, R. Varma, W. Cantrell, S.C. Chen, M. Gold, M. Muellenhoff, et al.
Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis.
J Eur Acad Dermatol Venereol, 23 (2009), pp. 42-45
C. Vlachou, A.I. Kanelleas, A. Martin-Clavijo, J. Berth-Jones.
Treatment of disseminated superficial actinic porokeratosis with topical diclofenac gel: a case series.
J Eur Acad Dermatol Venereol, 22 (2008), pp. 1343-1345
P.G. Calzavara-Pinton, M.T. Rossi, E. Aronson, R. Sala, Italian Group For Photodynamic Therapy.
A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: Inflammatory and aesthetic indications.
Photochem Photobiol Sci, 12 (2013), pp. 148-157
B. Ferrer Guillén, M.M. Giácaman, A. Pérez Ferriols.
Improved effect on 2 cases of disseminated superficial actinic porokeratosis with daylight photodynamic therapy.
Photodiagnosis Photodyn Ther, 23 (2018), pp. 365-366
D. Piccolo, D. Di Marcantonio, G. Crisman, G. Cannarozzo, M. Sannino, A. Chiricozzi, et al.
Unconventional use of intense pulsed light.
Biomed Res Int, 2014 (2014), pp. 618206
E. Ramelyte, M. Bylaite-Bucinskiene, R. Dummer, L. Imhof.
Successful use of grenz rays for disseminated superficial actinic porokeratosis: report of 8 cases.
Dermatology, 233 (2017), pp. 217-222
E.L. Gutierrez, C. Galarza, W. Ramos, M. Tello, P.C. De Paz, L. Bobbio, et al.
Facial porokeratosis: a series of six patients.
Aust J Dermatol, 51 (2010), pp. 191-194
A. Montes-Torres, C. Camarero-Mulas, D. de Argila, C. Gordillo, E. Daudén.
Inflammatory disseminated pruritic porokeratosis with a good response to ciclosporin.
Actas Dermosifiliogr, 107 (2016), pp. 261-262

Please cite this article as: Vargas-Mora P, Morgado-Carrasco D, Fustà-Novell X. Poroqueratosis. Revisión de su etiopatogenia, manifestaciones clínicas, diagnóstico y tratamiento. Actas Dermosifiliogr. 2020;111:545–560.

Copyright © 2020. AEDV
Actas Dermo-Sifiliográficas (English Edition)

Subscribe to our newsletter

Article options
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
  • Additional material
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
Supplemental materials
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.